Clinical Trial: Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity
Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity in Normal and Subcortical Vascular Cognitive Impairment Subjects
Brief Summary: The purpose of this study is to determine whether Zydena (Udenafil) has effect on cerebral blood flow and peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects.
Detailed Summary: Udenafil is a newly developed selective phosphodiesterase type 5 inhibitor (PDE5i). Since PDE5i is known to relax smooth muscle cells, it is suggested that PDE5i may dilate cerebral vessels and lead to an increase in cerebral blood flow. The main mechanism of subcortical vascular cognitive impairment are hypoperfusion of the brain. Therefore, in this study, the investigators will investigate whether Udenafil can increase cerebral blood flow and also lower peripheral blood viscosity in normal and subcortical vascular cognitive impairment subjects.
Sponsor: Samsung Medical Center
Current Primary Outcome: Cerebral blood flow [ Time Frame: One hour after the administration of the medication ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Peripheral blood viscosity [ Time Frame: One hour after the administration of the medication ]
Original Secondary Outcome: Same as current
Information By: Samsung Medical Center
Dates:
Date Received: November 3, 2011
Date Started: November 2011
Date Completion: November 2012
Last Updated: November 7, 2011
Last Verified: November 2011